HO95
Phase 3 Completed
1,503 enrolled
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Phase 3 Completed
706 enrolled 29 charts
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Phase 3 Completed
660 enrolled
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Phase 3 Completed
389 enrolled
MPRvsMEL200
Phase 3 Completed
402 enrolled
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Phase 3 Completed
220 enrolled
FOCUS
Phase 3 Completed
102 enrolled 1 FDA
EW-1
Phase 3 Completed
278 enrolled
IFM2014-02
Phase 3 Completed
300 enrolled
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Phase 3 Completed
665 enrolled 26 charts
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Phase 3 Completed
11 enrolled 6 charts
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Phase 3 Completed
93 enrolled
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Phase 3 Completed
205 enrolled 11 charts
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 3 Completed
595 enrolled
FIRST
Phase 3 Completed
1,623 enrolled 56 charts
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Phase 3 Completed
481 enrolled
CLARION
Phase 3 Completed
955 enrolled 20 charts
GEM2012MENOS65
Phase 3 Completed
460 enrolled
EMN-03
Phase 3 Completed
110 enrolled
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Phase 3 Completed
89 enrolled 11 charts
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
Phase 3 Completed
668 enrolled 7 charts
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Phase 3 Completed
130 enrolled 6 charts
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Phase 3 Completed
899 enrolled
DSMM-II
Phase 3 Completed
549 enrolled
UPFRONT
Phase 3 Completed
502 enrolled 17 charts
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Phase 3 Completed
56 enrolled
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
Phase 3 Completed
212 enrolled
High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
Phase 3 Completed
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase 3 Completed
340 enrolled
Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma
Phase 3 Completed
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Phase 3 Completed
216 enrolled
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
Phase 3 Completed
312 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
Phase 3 Completed
495 enrolled
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 3 Completed
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
Phase 3 Completed
400 enrolled
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
61 enrolled
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase 3 Completed
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
Phase 3 Completed
394 enrolled
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 3 Completed
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
Phase 3 Completed
280 enrolled
MAG 2002
Phase 3 Completed
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
Phase 3 Completed
122 enrolled
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Phase 3 Completed
100 enrolled